Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-Label Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nedosiran in Pediatric Patients From Birth to 11Years of Age With Primary Hyperoxaluria and Relatively Intact Renal Function

NCT05001269 is registered in ClinicalTrials.gov with Dicerna Pharmaceuticals, Inc., a Novo Nordisk company as lead sponsor.

NCT NCT05001269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05001269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-Label Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nedosiran in Pediatric Patients From Birth to 11Years of Age With Primary Hyperoxaluria and Relatively Intact Renal Function
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Phase
Phase 2
Overall status
Completed
Start date
February 22, 2022
Completion date
February 5, 2025
Enrollment
27 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

primary hyperoxaluria, primary hyperoxaluria type 1, primary hyperoxaluria type 2, primary hyperoxaluria type 3